Sentences with phrase «trial of an embryonic stem cell»

ACT, which has almost gone under several times in recent years, may now be on the verge of conducting the nation's first trial of an embryonic stem cell therapy, says Chief Scientific Officer Robert Lanza.

Geron became the first company to start clinical trials of embryonic stem cells in humans, starting with a patient who had spinal cord injuries.

In July, the FDA released its hold on the first trial of an embryonic stem cell based treatment, for spinal cord injury.

He said US scientists were pushing ahead and seeking regulatory approval to start safety trials of embryonic stem cells in spinal injury patients next year.

Not exact matches

The truth, of course, is that there are no human embryonic stem - cell therapies even in clinical trial, let alone ready for therapy, and there have been no major treatment....

Trials of cells made from human embryonic stem cells are also poised to begin in people with type 1 diabetes and heart failure, the first time embryonic stem cells have been used in the treatment of major lethal diseases.

Then, a team led by Robert Lanza, the chief scientific officer of Advanced Cell Technology Inc. in Marlborough, Massachusetts, and his colleagues published the first results ever of a clinical trial using human embryonic stem cells.

A clinical trial in the Republic of Korea for patients with degenerative eye diseases is the first to test the safety of an embryonic stem cell therapy for people of Asian descent.

Lanza previously led a clinical trial in the United States — published November 2014 in the Lancet — that demonstrated embryonic stem cells could be used safely for patients with degenerative eye diseases, but the patient sample was Caucasian with the exception of one African - American.

This will mark the start of the first clinical trial in China using human embryonic stem (ES) cells, and the first one worldwide aimed at treating Parkinson's disease using ES cells from fertilized embryos.

It has taken more than five years of graft, but at long last approval has been given for the first clinical trial using human embryonic stem cells (hESCs).

In the first published results from a clinical trial using human embryonic stem cells, two legally blind patients who received an injection of hESC - derived cells in one eye have experienced no harmful side effects and appear to have slightly better vision.

The trial is based on work from University of California at Irvine neuroscientist Hans Keirstead, who enabled paralyzed rats to walk again by coaxing embryonic stem cells to differentiate into the spinal cord cells that the rats had lost during injury.

by Paroma Basu Scientists grow critical nerve cells MADISON, WI — January 31, 2005 — After years of trial and error, scientists have coaxed human embryonic stem cells to become spinal motor neurons, critical nervous system pathways that relay messages from the brain to the rest of the body.

Advanced Cell Technology (OTC: ACTC, US) The whole world is eagerly watching the first results of clinical trials, involved embryonic stem cells.

At the International Society for Stem Cell Research 2017 Annual Meeting (June 14 - 17, 2017; Boston, USA), Asterias Biotherapeutics, Inc (CA, USA) will present new 9 - month efficacy and safety data from their ongoing SCiStar Phase I / IIa trial of human embryonic stem cell - derived oligodendrocyte progenitor ceStem Cell Research 2017 Annual Meeting (June 14 - 17, 2017; Boston, USA), Asterias Biotherapeutics, Inc (CA, USA) will present new 9 - month efficacy and safety data from their ongoing SCiStar Phase I / IIa trial of human embryonic stem cell - derived oligodendrocyte progenitor ceCell Research 2017 Annual Meeting (June 14 - 17, 2017; Boston, USA), Asterias Biotherapeutics, Inc (CA, USA) will present new 9 - month efficacy and safety data from their ongoing SCiStar Phase I / IIa trial of human embryonic stem cell - derived oligodendrocyte progenitor cestem cell - derived oligodendrocyte progenitor cecell - derived oligodendrocyte progenitor cells.

Preclinical Safety of Human Embryonic Stem Cell - Derived Oligodendrocyte Progenitors Supporting Clinical Trials In Spinal Cord Injury.

The birthday greeting contained an unintended irony, for while CIRM was approved by California voters a decade ago to give priority funding to human embryonic stem cell research, eight of the 10 approved clinical trials referenced by City of Hope were for research projects using adult and other non-embryonic stem cells.

The company had initially submitted its request to begin human trials with its RPE cells in November 2009, but has spent the past year addressing the FDA's concerns about the safety of the embryonic stem from which the RPE cells are made.

The Geron Corporation could be cleared to resume its stalled human embryonic stem cell (hESC)- trial for spinal cord injury in the third quarter of next year, linkurl: the company announced today; http://www.geron.com/media/pressview.aspx?id=1195 (October 30).

Other bodies, such as GTAC and the MHRA, will then be involved in the regulation of any clinical trials involving either embryonic or fetal stem cells.»

Treating Spinal Cord Injuries: 2009 also saw the first FDA - approval of the use of human embryonic stem cells in a clinical trial.

Federal officials have cleared a second clinical trial of a human embryonic stem - cell treatment, a company announced Monday, for a progressive blindness syndrome affecting young people.

The U.S. Food and Drug Administration has approved the second human trial of human embryonic stem cells — this one testing cells in people with a progressive form of blindness.

The challenge takes on even more urgency with recent developments, including a federal administration now more open to exploring the potential of stem cells, the recent FDA approval of a human trial involving embryonic stem cells, as well as the reported case of a young boy who developed a brain tumor four years after receiving a stem - cell treatment for a rare genetic disorder.

Late last year the preeminent firm in the field, Silicon Valley's Geron, abdicated its leadership position in the midst of the first - ever FDA - approved clinical trial for an embryonic - stem - cell therapy.